APP Podcast Playlist

Orchalgia

AUA podcasts

Copy of APP Podcast Playlist

You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.

AUAUniversity Podcast

Urolithiasis: Metabolic Evaluation and Medical Management

Support provided by independent educational grants from Astellas, Bayer HealthCare Pharmaceuticals Inc., Genentech, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., Merck and Pfizer, Inc.

CME Available: auau.auanet.org/node/31819

At the conclusion of this educational series, participants will be able to:
1. Discuss the impact of SDM on patients and on patient-clinician communication.
2. Identify at least one implementation strategy for using SDM in clinical practice.
3. Apply SDM techniques in a role-playing exercise with other colleagues.
4. Incorporate culturally sensitive communications to ensure quality SDM and reduce biases.
5. Utilize the knowledge and experience they have gained through role-play into their routine practice-counseling patients.

Improving Racial Disparities in Treatment Outcomes Podcast

NMIBC Guidelines

CME Available: https://auau.auanet.org/node/33093

At the conclusion of the activity, participants will be able to:
1. Describe recent developments in the medical management of advanced prostate cancer.
2. Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC.
3. Discuss clinical investigations in the treatment of advanced prostate cancer.
4. Analyze the risks and benefits of treatment for advanced prostate cancer.
5. Identify the criteria for genetic and genomic testing and utilize the results to improve outcomes among patients with advanced prostate cancer.

Acknowledgements
This educational activity is supported by independent educational grants from Astellas, AstraZeneca, Merck, Pfizer, Inc.

Live from AUA2021: Highlights in Advanced Prostate Cancer (2021)

CME Available: https://auau.auanet.org/node/33094

Acknowledgements
This educational activity is supported by an independent educational grant from:
Urovant

Live from AUA2021: Highlights in Overactive Bladder (2021)

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:

Treatment Intensification for Advanced Prostate Cancer

CME Available: https://auau.auanet.org/node/39486
Release Date: November, 2023
Expiration Date: November, 2024

LEARNING OBJECTIVES:
At the conclusion of these activities, participants will be able to:
1. Identify the latest developments in hormone therapy for advanced prostate cancer, including the use of novel treatments and combinations. 
2. Discuss the concept of doublet and triplet therapy in advanced prostate cancer and its rationale in enhancing treatment efficacy. 
3. Consider the challenges and future directions in implementing doublet and triplet therapy in clinical practice, including cost, accessibility, and patient selection.

ACKNOWLEDGEMENTS:
Support provided by independent educational grants from: 
Astellas and Pfizer, Inc.
AstraZeneca
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC 
Lantheus Medical Imaging
Merck & Co., Inc.

REFERENCES:
Freedland SJ, et al. Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer. NEJM Evidence. 2023.

Smith MR, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med 2022.

Fizazi K, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022.

Clarke NW, et al. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evidence. 2022

Chi KN, et al. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023.

Agarwal N, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023.

Treatment Intensification for Advanced Prostate Cancer

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:

Treatment Paradigms for Intermediate and High-Risk Non-Muscle Invasive Bladder Cancer 

CME Available: https://auau.auanet.org/node/39374
Release Date: December, 2023
Expiration Date: December, 2024

LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Describe the importance of individualized treatment decision-making and shared decision-making in the management of intermediate and high-risk NMIBC.
2. Discuss the challenges associated with BCG shortage and its impact on patient care and treatment decisions.
3. Evaluate alternative intravesical therapies for NMIBC, such as chemotherapeutic agents (e.g., mitomycin C, gemcitabine), novel immunotherapies (e.g., intravesical pembrolizumab), and clinical trials.

ACKNOWLEDGEMENTS:
Support provided by independent educational grants from: 
AstraZeneca
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC 
Lantheus Medical Imaging
Merck & Co., Inc.

Treatment Paradigms for Intermediate and High-Risk Non-Muscle Invasive Bladder Cancer

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:

Novel Imaging for Genitourinary Cancers - Diagnostics and Theranostics

CME Available: https://auau.auanet.org/node/39411
Release Date: December, 2023
Expiration Date: December, 2024

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:
1. Review the latest clinical trials investigating the use of PET imaging agents in prostate, kidney, and urothelial cancer, including their diagnostic accuracy and impact on patient management.
2. Discuss the available PET imaging agents for prostate cancer, with a specific focus on PSMA (Prostate-Specific Membrane Antigen) PET imaging, including its mechanism of action and its potential for detection of primary tumors, lymph node metastases, and distant metastases.
3. Discuss the benefits of incorporating PET imaging, including PSMA PET, in guiding treatment decisions for GU cancers, such as its impact on treatment selection, treatment response assessment, and the potential for theranostic approaches.

ACKNOWLEDGEMENTS:
Support provided by independent educational grants from: 
Astellas and Pfizer, Inc
AstraZeneca
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC 
Lantheus Medical Imaging
Merck & Co., Inc.

Novel Imaging for Genitourinary Cancers - Diagnostics and Theranostics

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:
The Latest Breakthroughs in Immunotherapy for GU Cancers

CME Available: https://auau.auanet.org/node/39543
Release Date: December, 2023
Expiration Date: December, 2024

LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Identify the newest immunotherapy drugs approved for prostate, bladder, and kidney cancer, including immune checkpoint inhibitors and other novel immunotherapies.
2. Discuss the clinical evidence supporting the use of these immunotherapy drugs in prostate, bladder, and kidney cancer, including data from pivotal clinical trials, response rates, and survival outcomes.
3. Evaluate the safety profile and potential immune-related adverse events associated with the newest immunotherapy drugs in GU cancers.

ACKNOWLEDGEMENTS:
Support provided by independent educational grants from: 
AstraZeneca
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC 
Lantheus Medical Imaging
Merck & Co., Inc.

The Latest Breakthroughs in Immunotherapy for GU Cancers

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:
Adjuvant Therapies for High-Risk Non-Metastatic Kidney Cancer 

CME Available: https://auau.auanet.org/node/39542
Release Date: December, 2023
Expiration Date: December, 2024

LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Identify the rationale behind using adjuvant therapies in high-risk non-metastatic kidney cancer and the goals of adjuvant treatment.
2. Describe the adjuvant therapies that have been investigated to date for high-risk non-metastatic kidney cancer, including targeted therapies, immunotherapies, and combination approaches.
3. Discuss the challenges and limitations associated with adjuvant therapy trials in high-risk non-metastatic kidney cancer, such as patient selection, trial design, and long-term follow-up.

ACKNOWLEDGEMENTS:
Support provided by independent educational grants from: 
AstraZeneca
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC 
Lantheus Medical Imaging
Merck & Co., Inc.

Adjuvant Therapies for High-Risk Non-Metastatic Kidney Cancer

AUA2025: Key Takeaways: BPH 

Presenters: Bilal Chughtai, MD & Dean S. Elterman, MD, MSc, FRCSC

AUA2025: Key Takeaways: BPH

Core Curriculum: Surgical Management of Urolithiasis

AUA Urology Core Curriculum: auau.auanet.org/core

Host: Mark L. Gonzalgo, MD, PhD, MBA
Guests: Marcelino E. Rivera, MD and T. Max Shelton, MD

Outline:
Segment 1: Acute Stone Event and Radiographic Evaluation
Segment 2: Shock Wave Lithotripsy
Segment 3: Ureteroscopy
Segment 4: Percutaneous Nephrolithotomy
Segment 5: Intracorporeal Lithotripsy
Segment 6: Special Considerations

Core Curriculum: Surgical Management of Urolithiasis

LG-IR-NMIBC Treatment Landscape 

Host: Mark L. Gonzalgo, MD, PhD, MBA
Guest: Chad R. Ritch, MD, MBA, FACS

CME Available: auau.auanet.org/node/44036

ACKNOWLEDGEMENTS:
Support provided by independent educational grants from: 
AstraZeneca
Johnson & Johnson

LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Differentiate between traditional and emerging intravesical therapies for LG-IR-NMIBC, considering mechanism of action, administration schedules, and patient eligibility to support individualized treatment planning.
2. Incorporate into practice shared decision-making strategies that align clinical recommendations with patient values, preferences, and quality-of-life considerations in the management of LG-IR-NMIBC.
3. Utilize practical approaches for integrating intravesical therapy into routine clinical workflows, including coordination among multidisciplinary teams, patient education, and follow-up to optimize adherence and outcomes.

LG-IR-NMIBC Treatment Landscape

AUA Guidelines: Genitourinary Syndrome of Menopause 

Host: Mark L. Gonzalgo, MD, PhD, MBA
Guests: Tracey S. Wilson, MD & Una J. Lee, MD

Genitourinary Syndrome of Menopause: AUA/SUFU/AUGS Guideline (2025)
Kaufman MR, Ackerman LA, Amin KA, et al. The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause. J Urol. 0(0). doi:10.1097/JU.0000000000004589. https://www.auajournals.org/doi/10.1097/JU.0000000000004589

AUA Guidelines: Genitourinary Syndrome of Menopause

MIBC Treatment Landscape

Host: Mark L. Gonzalgo, MD, PhD, MBA
Guest: Jen-Jane Liu, MD, FACS

CME Available: auau.auanet.org/node/44077

ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:
AstraZeneca
Johnson & Johnson

LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Integrate immunotherapy and targeted therapy into the multimodal management of MIBC, selecting appropriate regimens and sequencing strategies based on current guidelines, clinical trial data, and patient-specific factors.
2. Evaluate the clinical role, mechanisms of action, and evidence base for targeted therapies in MIBC, including biomarker-driven selection to support personalized treatment planning.
3. Develop and apply practical approaches for preventing, monitoring, and managing immune-related adverse events and other toxicities associated with immunotherapy and targeted therapy to optimize patient safety, adherence, and quality of life.

MIBC Treatment Landscape

Co-Host: Brian Shuch, MD

At the conclusion of these activities, participants will be able to:
1. State the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men.
2. Describe results of genetic testing and relay this information to patients in order to facilitate shared-decision making based on the test results.
3. Explain the importance of testing for germline mutations and their implication for novel therapies such as PARP inhibitors.

CME Available: https://auau.auanet.org/node/26054

This educational series is supported by independent educational grants from:
Amgen
Astellas
AstraZeneca
Bristol-Myers Squibb
Genomic Health
Merck
Pfizer, Inc.
Sanofi Genzyme
UroGen Pharma

Genetic Testing in Prostate Cancer

Co-Host: Jay Raman, MD, FACS

At the conclusion of these activities, participants will be able to:
1. Review the mechanisms of action, efficacy, and safety of currently available targeted treatment of RCC.
2. Facilitate discussions with patients and caregivers regarding RCC treatment options.

CME Available: auau.auanet.org/node/26091

This educational series is supported by independent educational grants from:
Amgen
Astellas
AstraZeneca
Bristol-Myers Squibb
Genomic Health
Merck
Pfizer, Inc.
Sanofi Genzyme
UroGen Pharma

Targeted Therapies In Renal Cell Carcinoma

2019 AUA Annual Meeting Presidential Address
Robert Flanigan, MD, FACS
Loyola University Chicago Stritch School of Medicine

2019 Presidential Address: Urologic Research: Why is it So Important to Us

Moderator: 
Seth Cohen, MD

Panelists: 
Gina Badalato, MD
Kathleen Kieran, MD
Kyle Zuniga (MS4)
Vincent D'Andrea (MS4)

Rotating On The Urology Service  Facts And Strategy For Medical Students

Host: Victor Nitti, MD
Guest: David Shin, MD

Chronic orchialgia or testicular pain is a challenging disease to treat for both the patient and urologist because the perception and resolution of pain is often subjective in nature. With a national trend towards treatment away from opioid use, it is important that clinicians utilize an algorithm focusing on non-narcotic use for medication treatment as well as be able to offer office-based or surgical therapies when medical therapy fails.
After today’s podcast, learners will be able to:
1. Compare and contrast pathological and non-pathological etiologies of scrotal pain
2. Summarize the rationale for different medication therapies and incorporate an algorithm for treatment
3. Distinguish various surgical treatment options depending upon etiology

Chronic Orchialgia - An Algorithm For Successful Treatment

The AUAUniversity podcast is an official podcast of the American Urological Association.  More information can be found at https://auau.auanet.org